67 related articles for article (PubMed ID: 20361296)
1. This Month in APR.
Lee JY
Arch Pharm Res; 2010 Mar; 33(3):335-7. PubMed ID: 20361296
[No Abstract] [Full Text] [Related]
2. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the effect of picotamide on platelet function in diabetic subjects].
Carleo R; Veno L; Fuccio F; Bonavita M; De Matteo A; Gallo M; Gatti A; Gobbo M; Nocerino L
Boll Soc Ital Biol Sper; 1990 Jul; 66(7):647-54. PubMed ID: 2083059
[TBL] [Abstract][Full Text] [Related]
6. ONO-AP-500-02: a non prostanoid prostaglandin I2 mimetic with inhibitory activity against thromboxane synthase.
Kondo K; Machii K; Narita M; Kawamoto A; Yamasaki S; Hamanaka N
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():401-3. PubMed ID: 7732882
[No Abstract] [Full Text] [Related]
7. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
8. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
10. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development.
Patrono C; Patrignani P; Rocca B; Landolfi R
Thromb Haemost; 1995 Jul; 74(1):396-400. PubMed ID: 8578493
[No Abstract] [Full Text] [Related]
11. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
12. New pyridazino[4,5-b]indole derivatives with inodilator and antiaggregatory activities.
Monge A; Aldana I; Losa MJ; Font M; Cenarruzabeitia E; Castiella E; Frechilla D; Santiago E; Martínez de Irujo JJ; Alberdi E
Arzneimittelforschung; 1993 Nov; 43(11):1175-80. PubMed ID: 8292060
[TBL] [Abstract][Full Text] [Related]
13. [Status and trends in the field of inhibitors of thrombocyte function].
Glusa E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):575-9. PubMed ID: 6083929
[TBL] [Abstract][Full Text] [Related]
14. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
[TBL] [Abstract][Full Text] [Related]
15. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism of changes in the platelet functional activity caused by low energy laser irradiation].
Spasov AA; Nedogoda VV; Konan K
Biull Eksp Biol Med; 1998 Jul; 126(7):45-8. PubMed ID: 9777195
[No Abstract] [Full Text] [Related]
17. The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity.
Park WH; Kim KS; Kim KH; Kim DS; Kim CH
Int Immunopharmacol; 2003 Jul; 3(7):971-8. PubMed ID: 12810354
[TBL] [Abstract][Full Text] [Related]
18. [Use of a thromboxane synthetase inhibitor for the protection of platelet number and function during extracorporeal circulation. Experimental study].
Massonnet Castel S; Pelissier E; Fabiani JN; Terrier E
Agressologie; 1983 Dec; 24(12):605-8. PubMed ID: 6686919
[No Abstract] [Full Text] [Related]
19. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
[TBL] [Abstract][Full Text] [Related]
20. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
